OPTN - OptiNose: Undiscovered Gem

• According to OptiNose's management, in 2021, the company's revenue will be at least $80 million, which is 62.9% more than in 2020.
• The company's gross margin is around 87%, well above the pharmaceutical industry average.
• Xhance sales increased 78.6% in Q2 2021 compared to Q2 2020.
• In addition, the company is expected to announce the results of two phase III clinical trials in the next 12 months. They are highly likely to be positive based on the results of the interim study.
• The number of physicians who prescribed Xhance for the first time in Q2 was 7,188, up 15.8% from a year earlier.

For further details see: